GlassScriptPhysician profile
Mary Ngugi
NPI 1972106615
$1,956.86
in general payments reported to CMS, 2019-2025
18 companies · $750 in 2025
The $750 reported for 2025 was more than what 75% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $45.78 · 2022: $126 · 2023: $185 · 2024: $850 · 2025: $750.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,722 · Education: $62.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,722.01 |
| Education | $62.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $431.57 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $224.15 | 2022-2025 | Caplyta |
| Lundbeck LLC | $220.63 | 2024-2025 | Abilify Asimtufii, Rexulti |
| Otsuka America Pharmaceutical, INC. | $177.40 | 2021-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Vanda Pharmaceuticals INC. | $163.01 | 2025 | Fanapt |
| Janssen Pharmaceuticals, INC | $135.55 | 2022-2025 | Invega Sustenna, Spravato |
| Alkermes, INC. | $117.68 | 2021-2025 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $94.85 | 2024-2025 | Ingrezza |
| Corium, LLC | $91.90 | 2024-2025 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $70.95 | 2024-2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $64.89 | 2024-2025 | Uzedy |
| Takeda Pharmaceuticals U.S.A., INC. | $45.47 | 2024-2025 | Trintellix |
| Almatica Pharma LLC | $26.42 | 2023 | Loreev Xr |
| Axsome Therapeutics, INC. | $24.67 | 2024 | Auvelity |
| Supernus Pharmaceuticals, INC. | $18.51 | 2025 | Qelbree |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $18.08 | 2024 | Quviviq |
| Indivior INC. | $17.44 | 2024 | Perseris |
| Noven Therapeutics, LLC | $13.69 | 2025 | Xelstrym, Secuado |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Ngugi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.